Endocrinology Unit, Azienda Sanitaria-Universitaria Friuli Centrale, P.O. Santa Maria della Misericordia, Udine, Italy.
Department of Endocrinology, Diabetes and Metabolism, Ospedale Santa Croce and Carle Hospital, Cuneo, Italy.
Endocr Metab Immune Disord Drug Targets. 2024;24(8):991-1006. doi: 10.2174/0118715303260423231122111705.
This guideline (GL) is aimed at providing a clinical practice reference for the management of sporadic primary hyperparathyroidism (PHPT) in adults. PHPT management in pregnancy was not considered.
This GL has been developed following the methods described in the Manual of the Italian National Guideline System. For each question, the panel appointed by Associazione Medici Endocrinology (AME) and Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (SIOMMMS) identified potentially relevant outcomes, which were then rated for their impact on therapeutic choices. Only outcomes classified as "critical" and "important" were considered in the systematic review of evidence. Those classified as "critical" were considered for the clinical practice recommendations.
The present GL provides recommendations about the roles of pharmacological and surgical treatment for the clinical management of sporadic PHPT. Parathyroidectomy is recommended in comparison to surveillance or pharmacologic treatment in any adult (outside of pregnancy) or elderly subject diagnosed with sporadic PHPT who is symptomatic or meets any of the following criteria: • Serum calcium levels >1 mg/dL above the upper limit of normal range. • Urinary calcium levels >4 mg/kg/day. • Osteoporosis disclosed by DXA examination and/or any fragility fracture. • Renal function impairment (eGFR <60 mL/min). • Clinic or silent nephrolithiasis. • Age ≤50 years. Monitoring and treatment of any comorbidity or complication of PHPT at bone, kidney, or cardiovascular level are suggested for patients who do not meet the criteria for surgery or are not operated on for any reason. Sixteen indications for good clinical practice are provided in addition to the recommendations.
The present GL is directed to endocrinologists and surgeons - working in hospitals, territorial services or private practice - and to general practitioners and patients. The recommendations should also consider the patient's preferences and the available resources and expertise.
本指南(GL)旨在为成人散发性甲状旁腺功能亢进症(PHPT)的管理提供临床实践参考。未考虑妊娠期间的 PHPT 管理。
本 GL 遵循意大利国家指南系统手册中描述的方法制定。对于每个问题,由 Associazione Medici Endocrinology(AME)和 Società Italiana dell'Osteoporosi、del Metabolismo Minerale e delle Malattie dello Scheletro(SIOMMMS)任命的专家组确定潜在相关的结局,然后对这些结局对治疗选择的影响进行评分。只有被归类为“关键”和“重要”的结局才会在证据的系统回顾中进行考虑。被归类为“关键”的结局将被用于临床实践建议。
本 GL 提供了关于药物治疗和手术治疗在散发性 PHPT 临床管理中的作用的建议。与监测或药物治疗相比,甲状旁腺切除术推荐用于任何患有散发性 PHPT 的成年(妊娠除外)或老年患者,这些患者有症状或符合以下任何标准:
血清钙水平比正常范围上限高出 1 毫克/分升以上。
尿钙水平>4 毫克/公斤/天。
DXA 检查显示骨质疏松症和/或任何脆性骨折。
肾功能受损(eGFR<60 毫升/分钟)。
临床或无症状的肾结石。
年龄≤50 岁。
对于不符合手术标准或因任何原因未接受手术的患者,建议监测和治疗 PHPT 在骨骼、肾脏或心血管水平的任何合并症或并发症。除了建议之外,还提供了十六项良好临床实践的指征。
本 GL 面向在医院、地区服务或私人诊所工作的内分泌学家和外科医生,以及全科医生和患者。建议还应考虑患者的偏好以及可用的资源和专业知识。